<div><p><strong><span><b>Background:</span> </b></strong></p>

<div><p><strong><b>Background:</strong> </b>Severe alcoholic hepatitis (SAH) is associated with malnutrition, dysbiosis and inflammatory cytokines augmenting liver injury resulting in high mortality. Experimental studies have reported that in comparison to unsaturated fat (UF), saturated fat (SF) improves dysbiosis, inflammation, liver enzymes and protects against alcoholic liver injury, but effect on clinical outcome and gut microbiota (GM) in SAH patients is lacking.</p>

<div><p><b>Background: </b>Immune checkpoint therapies combination with anti-VEGF is the standard-of-care in first-line of hepatocellular carcinoma (HCC). However, only 30 % of patients present a response to first line therapy. Autophagy inhibitors were recently spotted out as a potential robust strategy to promote antigen presentation and therefore reinforce immune checkpoint inhibitors (ICIs) potency conducting to strong anti-tumoral response.

<div><p><strong>Background</strong>: Sarcopenia in end-stage liver disease (ESLD) has been identified as a risk factor for increased mortality. Radiological parameters; psoas muscle area index (PMAI) &amp; transverse psoas muscle thickness index (TPMTI) assess muscle quantity. While psoas muscle density index (PMDI) assesses muscle quality. Both identify muscle wasting, atrophy &amp; myosteatosis.</p>

<div><p><strong><b>Background:</strong> </b>Nonalcoholic steatohepatitis (NASH) is a progressive disease characterized by liver inflammation. Emerging evidence implicates T cells in the disease pathogenesis. Our unpublished data show that CD4 T cells contribute to NASH development; however, hepatic CD4 T cell phenotypes and functions in NASH have not yet been systematically examined.</p>

<div><p><b>Background: </b>Viral hepatitis screening and link to care is a key cancer control strategy to prevent development of liver cancer, especially in underserved populations. We lack data on determinants for viral hepatitis and liver cancer screening and care particularly in geographically spread Asian American (AA) populations.</p>

<div><p><b>Background:</p> </b><p>Immigrants are the largest subgroup living with chronic hepatitis B (HBV) infection in the United States (US). Close monitoring is recommended for all patients with chronic HBV regardless of disease activity. It is not well understood how immigration factors and social determinants of health (SDOH) impact downstream adherence to HBV monitoring among immigrants.</p>

<div><p><b>Background: </b>Despite advances in understanding the pathophysiology of nonalcoholic steatohepatitis (NASH), no pharmacotherapy has been proven effective in improving outcome. Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors with key role in metabolic homeostasis and inflammation and PPAR knockout mice are susceptible to development of NASH. Studies have shown protective role of PPAR-α in hepatic steatosis and inflammation and PPAR-γ as insulin sensitizers.

<div><p><b>Background:</p> </b><p>The identification of at-risk metabolic dysfunction-associated steatohepatitis (MASH) patients remains a main challenge in both clinical practice and clinical trial settings. Several non-invasive biomarkers have been developed to identify those at-risk MASH patients who would benefit from pharmacological therapy. We aimed to describe the main predictors of at-risk MASH across multiple therapeutic clinical trials.</p>

<div><p><strong><b>Background:</strong> </b>Chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, contribute significantly to liver-related morbidity and mortality. Statins, commonly prescribed for dyslipidemia, have been suggested to possess hepatoprotective effects beyond their lipid-lowering properties.